Assembly Actions -
Lowercase Senate Actions - UPPERCASE |
|
---|---|
Jun 19, 2018 |
referred to health delivered to assembly passed senate ordered to third reading cal.1949 committee discharged and committed to rules |
Feb 09, 2018 |
referred to health |
Senate Bill S7710
2017-2018 Legislative Session
Sponsored By
(D, WF) 46th Senate District
Archive: Last Bill Status - In Assembly Committee
- Introduced
-
- In Committee Assembly
- In Committee Senate
-
- On Floor Calendar Assembly
- On Floor Calendar Senate
-
- Passed Assembly
- Passed Senate
- Delivered to Governor
- Signed By Governor
Actions
Votes
2017-S7710 (ACTIVE) - Details
- See Assembly Version of this Bill:
- A11279
- Current Committee:
- Assembly Health
- Law Section:
- Public Health Law
- Laws Affected:
- Add §2400-a, Pub Health L; amd §§3216, 3221 & 4303, Ins L; add §365-o, Soc Serv L
- Versions Introduced in Other Legislative Sessions:
-
2019-2020:
S984, A7533
2021-2022: S1462, A3191
2017-S7710 (ACTIVE) - Summary
Requires dihydropyrimidine dehydrogenase deficiency testing prior to fluoropyrmidine or other antimetabolite treatment; requires policies and contracts of insurance to include coverage for dihydropyrimidine dehydrogenase deficiency testing; provides for dihydropyrimidine dehydrogenase deficiency testing under the medical assistance program.
2017-S7710 (ACTIVE) - Sponsor Memo
BILL NUMBER: S7710 SPONSOR: BRESLIN TITLE OF BILL: An act to amend the public health law, in relation to requiring dihydropyrimidine dehydrogenase deficiency testing for certain individuals with cancer; to amend the insurance law, in relation to requiring policies and contracts of insurance to include coverage for dihydropyrimidine dehydrogenase deficiency testing; and to amend the social services law, in relation to the provision of dihydropyrimidine dehydrogenase deficiency testing under the medical assistance program PURPOSE OR GENERAL IDEA OF BILL: To allow cancer patients being treated with chemotherapy involving Fluo- rouracil (5FU) to be tested for Dihydropyrimidine Dehydrogenase Defi- ciency (DPD) prior to treatment. SUMMARY OF SPECIFIC PROVISIONS: Section One amends the public health law by adding a new section, 2400-a, which will define terms and language used in the bill, and will
2017-S7710 (ACTIVE) - Bill Text download pdf
S T A T E O F N E W Y O R K ________________________________________________________________________ 7710 I N S E N A T E February 9, 2018 ___________ Introduced by Sen. BRESLIN -- read twice and ordered printed, and when printed to be committed to the Committee on Health AN ACT to amend the public health law, in relation to requiring dihydro- pyrimidine dehydrogenase deficiency testing for certain individuals with cancer; to amend the insurance law, in relation to requiring policies and contracts of insurance to include coverage for dihydropy- rimidine dehydrogenase deficiency testing; and to amend the social services law, in relation to the provision of dihydropyrimidine dehyd- rogenase deficiency testing under the medical assistance program THE PEOPLE OF THE STATE OF NEW YORK, REPRESENTED IN SENATE AND ASSEM- BLY, DO ENACT AS FOLLOWS: Section 1. The public health law is amended by adding a new section 2400-a to read as follows: § 2400-A. DIHYDROPYRIMIDINE DEHYDROGENASE DEFICIENCY TESTING. 1. FOR PURPOSES OF THIS SECTION THE FOLLOWING TERMS SHALL HAVE THE FOLLOWING MEANINGS: (A) "ANTIMETABOLITES" MEANS A SUBSTANCE THAT INTERFERES WITH THE NORMAL METABOLIC PROCESSES WITHIN CELLS, TYPICALLY BY COMBINING WITH ENZYMES. (B) "DIHYDROPYRIMIDINE DEHYDROGENASE DEFICIENCY" MEANS A CONDITION IN WHICH THE BODY CANNOT BREAK DOWN THE NUCLEOTIDES THYMINE AND URACIL. (C) "FLUOROPYRMIDINE" MEANS A GROUP OF SUBSTANCES USED TO TREAT CANCER THROUGH CHEMOTHERAPY. 2. EVERY PHYSICIAN OR OTHER AUTHORIZED PRACTITIONER WHO PROVIDES FLUO- ROPYRMIDINE OR OTHER ANTIMETABOLITES TO INDIVIDUALS DIAGNOSED WITH CANCER SHALL TEST FOR DIHYDROPYRIMIDINE DEHYDROGENASE DEFICIENCY PRIOR TO SUCH TREATMENT. § 2. Subparagraph (A) of paragraph 12-a of subsection (i) of section 3216 of the insurance law, as amended by chapter 12 of the laws of 2012, is amended to read as follows: (A) Every policy delivered or issued for delivery in this state that provides medical, major medical, or similar comprehensive-type coverage and provides coverage for prescription drugs and also provides coverage for cancer chemotherapy treatment shall provide coverage for prescribed, EXPLANATION--Matter in ITALICS (underscored) is new; matter in brackets
Comments
Open Legislation is a forum for New York State legislation. All comments are subject to review and community moderation is encouraged.
Comments deemed off-topic, commercial, campaign-related, self-promotional; or that contain profanity, hate or toxic speech; or that link to sites outside of the nysenate.gov domain are not permitted, and will not be published. Attempts to intimidate and silence contributors or deliberately deceive the public, including excessive or extraneous posting/posts, or coordinated activity, are prohibited and may result in the temporary or permanent banning of the user. Comment moderation is generally performed Monday through Friday. By contributing or voting you agree to the Terms of Participation and verify you are over 13.
Create an account. An account allows you to sign petitions with a single click, officially support or oppose key legislation, and follow issues, committees, and bills that matter to you. When you create an account, you agree to this platform's terms of participation.